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Chlamydia trachomatis (CT) is the most common cause of bacterial sexually transmitted infection (STI) worldwide, but current
data concerning the prevalence of CT among women in Iran is scarce. Data regarding the frequency of CT infection among
Iranian women can help to justify the implementation of a national CT screening program that can reduce the high morbidity
associated with sequelae of CT infections by treating infected women. Endocervical secretions from 123 married women (20–55
years) with cervicitis were tested by a PCR-EIA method using primers to amplify a CT-speciﬁc plasmid. The digoxigenin-labeled
amplicon was measured by hybridization to a biotin-labeled probe and a strepavidin-coated plate, followed by an enzyme-linked
colorimetric analysis. Overall frequency of CT infection among women was 17% (21/123). The range of CT frequency among
various age groups was 12–25%. The 31–40-year-age group comprised the majority (49%) of CT positive samples, followed by
20–30yeargroup(33%).Althoughthe20-to-30-year-oldwomenreportedthehighestfrequencyofSTIhistory,theyhadthelowest
relative frequency of CT infection (12%). There is a high frequency of CT infection among women with cervicitis in Tehran, Iran,
thus indicating a necessity to implement a routine CT screening program in the major cities of Iran and possibly nationwide.
Identiﬁcation of CT-infected women may prevent its spread, and thereby reduce the high morbidity associated with CT infections
among women in Iran.
Copyright © 2007 Farhad B. Hashemi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Chlamydia trachomatis (CT) is the most common cause of
bacterial sexually transmitted infections (STI), with millions
of cases reported annually throughout the world [1]. Most
genital CT infections in women are asymptomatic; however,
chlamydial infections can commonly lead to sequelae com-
plications such as pelvic inﬂammatory disease (PID), an in-
creased risk of ectopic pregnancy, and infertility [2, 3]. Early
diagnosis is essential for the timely treatment of CT-infected
women to prevent the development of sequelae and prevent-
ing the transmission of CT to susceptible individuals. Na-
tionalscreeningprogramsthatidentifyandtreatCT-infected
women have been shown to reduce the rates of CT infections
and the morbidity associated with CT infections [4, 5]. Re-
grettably, nationwide STI surveillance programs are absent
in Iran, and a majority of women have inadequate access
to reproductive health services or STI clinics. Consequently,
information concerning the prevalence of CT among women
in Iran is scarce. Current data regarding CT infection from a
region is essential for controlling its spread and for helping
assesstheimpactofCTonthereproductivehealthofwomen.
In this small study, we report the incidence of CT infection
among women with cervicitis in Tehran, Iran.
2. MATERIALS AND METHODS
2.1. Patientsandspecimens
Atotalof123marriedwomen(aged20–55years)withsymp-
tomaticcervicitisparticipatedinthiscaseseriesstudy.Partic-
ipants visited the obstetrics and gynecology section of Mirza
Kouchek Khan Hospital in Tehran, Iran, between Decem-
ber 2004 to June 2005, primarily complaining of pelvic pain
and/or vaginal discharge. All women who received antibi-
otic treatment within three weeks prior to their visit were
excluded from our study. Consenting participants completed
a questionnaire before cervical examination in which they
were asked for demographic data and any STI history (i.e.,
self-reported). Cervical examination included the evaluation2 Infectious Diseases in Obstetrics and Gynecology
forthepresenceofmucopurulentendocervicaldischarge,fri-
ability, and ectropin. After removing cervical mucus, sam-
ples of the endocervical canal secretions were collected on
twocottonswabs,whichwerewashedin500µLofphosphate
buﬀered saline and the ﬂuid was stored at −20◦C. DNA was
extracted from 100µL of the endocervical sample ﬂuid using
the DIAtom Prep100 kit (IsoGene Inc., Moscow, Russia) and
was stored at −20◦C until used.
2.2. PCRampliﬁcation
This method has been described in detail elsewhere [6].
Brieﬂy, a 377bp fragment of a cryptic plasmid (speciﬁc to
C. trachomatis) was ampliﬁed through 30 cycles (pre-dena-
turation step at 94◦C 3.5min, denaturation at 94◦C3 0 s ,
primer annealing at 52◦C, and 30s primer extension at
72◦C3 m i n )i n2 5 µLP C Rr e a c t i o nb u ﬀer (consisting of
10mmol/L TRIS, pH 8.3, 50mmol/L KC1, 2.5mmol/L
MgCl2,a n d0 .01% gelatin); 0.2mmol/L each of dATP, dGTP,
dCTP,anddTTP;2.5UTaq DNApolymerase;and0.5µmol/L
primers for conserved plasmid nucleotide sequences of C.
trachomatis (Table 1).
2.3. PCR-EIA
The amplicon was measured by the detection of digoxigenin-
labeled C. trachomatis PCR products in a microtiter-based
enzyme immunoassay (PCR-EIA). Brieﬂy, 10µL of ampli-
c o nw a sd e n a t u r e dw i t h2 0 µL NaOH and incubated at
room temperature (RT), and after 10min, 220µLo fh y -
bridization buﬀer containing 10pmol of the 5  end biotin-
labeled CT-speciﬁc internal oligonucleotide probe (comple-
mentary to the primers) was added. The amplicon was hy-
bridized in solution for 30min at 54◦C, and the mixture was
added to a strepavidin-coated 96-well microtiter plate. Using
a hybridization-based EIA (Roche Diagnostics, Mannheim,
Germany), 200µL of 1 : 100 diluted peroxidase-conjugated
antidigoxigenin IgG was added to each well, incubated for
30min at 37◦C. After the wash (5X), 200µL of the ABTS
substrate solution was added, and the plate was incubated
for 30min at 37◦C. The optical density (OD) of the samples
was measured by spectrophotometry at 405nm absorbance
(reference ﬁlter: 492nm). The PCR-EIA run was considered
valid if (−)c o n t r o lO Dv a l u e sw e r e<0.1, and the PCR pos-
itive control value was >1.0. The background OD value was
0.055, calculated as the mean of all (−) control samples plus
3 standard deviations (SD). A sample was considered (+) if
its OD value was greater than the background cutoﬀ value
by threefold (i.e., 0.165). The mean OD value of CT positive
control samples was 1.81 ± 0.789.
3. RESULTS
Table 2 shows the rates of C. trachomatis infection among
all four age groups of married women studied. Overall,
17% (21/123) of the specimens were positive for chlamy-
dial DNA by the PCR-EIA assay. The CT infection frequency
rate ranged from 12% to 25% among the patient age groups
Table 1:TheDNAsequence ofPCRprimersandtheprobeusedfor
detection of C. trachomatis by PCR-EIA assay.
Primer/probe name DNA sequence (5  → 3 )
BP1 (sense) AACCGTTTTTAATAGTGGCA
BP2 (antisense) TTCTGGCCAAGAATTATCC
BP3 (probe) AGCAGCTGCGAAAAAGAGAC
(Table 2). Although the 31–40-year group represented 35%
of the samples, this age group comprised a marked 49%
(10/21) of CT positive samples. Conversely, the 20–30-year
group, which represented about half the patients investi-
gated, comprised only 33% (7/21) of the C. trachomatis posi-
tive samples. Interestingly, when these two groups were com-
bined, the 20–40-year group represented 81% of women in
this study, and their samples comprised 81% of all CT posi-
tive specimens, as well.
On the other hand, as Table 2 demonstrates, when the
CT positive samples were adjusted for the number of speci-
menswithineachagegroupofwomen,thehighestrateofCT
positive samples (25%) was from the >51-year-old women
(1/4), however, the >51-year-age group represented <1% of
thesamplesstudied.The31–40agegroupshowedthesecond
highest rate of CT infection with 23.3% (10/43), followed by
the 41–50-year-old women comprising 15.8% (3/19) of CT
positive samples.
Overall, 29% (36/123) of patients reported to have STI
history. Interestingly, even though the youngest group (20–
30 years) in our study reported the highest adjusted rate of
STI history 35% (20/57), these women showed the lowest
(12.3%) adjusted frequency of CT infection with (Table 2).
With the exception of the 31–40-year-age group, among all
age groups investigated, the proportion of women who ad-
mitted to having a history of STI was higher than that of
those with genital CT infection (Table 2).
4. DISCUSSION
The 17% frequency rate of CT genital infections among mar-
r i e dw o m e ni nI r a ni si nc o n t r a s tw i t ht h e7 %r a t ep r e v i -
ously reported from Iran in the early 1980s [7]. Although
the patients in neither study are representative of the general
population, including asymptomatic women, the current CT
infection rate is higher than the 4–11% prevalence rates re-
ported from Slovenia, Holland, Colombia, Canada, and the
United States [5, 8–11]. The diﬀerence in genital CT infec-
tion rate among women in this study as compared to recent
reports from Tehran [6, 12] may relate to the improved sen-
sitivity of the PCR-EIA employed, as well as the diﬀerences
in the type of patients and specimens analyzed.
Our ﬁndings highlight the need for routine CT screen-
ing, particularly among Iranian women aged <40 years, for
early detection of genital chlamydial infection to reduce the
morbidity associated with sequelae. It has been shown that
the level of chlamydial cervicitis decreases quickly in coun-
tries where routine screening for CT has become mandatory
[4]. Early diagnosis and appropriate treatment of chlamydialFarhad B. Hashemi et al. 3
Table 2: Frequency of C. trachomatis infection among women with cervicitis according to their age groups. (CT = C. trachomatis;S T I=
sexually transmitted infection.)
Age group Patient number (+) STI history (+) CT % (+) CT % (+) CT
(year) (%) number (%∗) number (of total∗) (within each age group)
20–30 57 (47) 20 (16) 7 5.7% 12.3%
31–40 43 (35) 8 (7) 10 8.1% 23.3%
41–50 19 (15) 4 (3) 3 2.4% 15.8%
≥ 51 4 (3) 4 (3) 1 0.8% 25.0%
Total 123 (100) 36 (29) 21 17.0—
77∗Of total number of specimens studied (N = 123).
cervicitis among the younger women will help to prevent
transmission of C. trachomatis to susceptible individuals and
avoid severe complications that eventually develop in older
women. Initially, screening programs may focus on patients
visiting the infertility or STI clinics in large cities of Iran and
can later expand to cover the symptomatic as well as asymp-
tomatic CT-infected women throughout the country.
We acknowledge that our results would have been en-
hanced by a larger sample size as well as additional de-
mographic and behavioral data (i.e., socioeconomic status)
which would have allowed for advanced data analysis. Over-
coming obstacles, which hinder studies like ours, such as the
social stigma associated with patients visiting the STD clinics
plus increasing the number of women’s health centers oﬀer-
ing diagnostic services for management of CT cervicitis can
make a signiﬁcant impact on women’s reproductive health
by preventing the long-term sequelae associated with PID
[3, 13]. Nevertheless, our data lends support to implement-
ing a nationwide screening program to identify and treat
Iranian women with CT infections using sensitive methods.
Other countries have shown that such programs are cost-
eﬀective and can lead to reduced morbidity associated with
chlamydial infections [14]. Since most women with genital
chlamydial infection are asymptomatic, and our study did
not include this group of women, the rate of CT infection
might be higher than 17% among women in Tehran. There-
fore, improving the status of women’s reproductive health
care services is well justiﬁed in the large cities of Iran.
To the best of our knowledge, this is the ﬁrst report from
Iranthatprovidescurrentdataregardingfrequencyofgenital
CT infection among married Iranian women with cervicitis,
and may be particularly helpful to physicians treating such
patients in Iran, where the quality of women’s health care re-
quires drastic improvement.
In conclusion, the high frequency of CT genital infec-
tions among married women in Iran warrants a compre-
hensive study to screen a large number of women suﬀering
from chlamydial infection, thus allowing for better estimates
of the real magnitude of the reservoir of asymptomatic CT
infections among Iranian women. In light of studies that
have shown chlamydial genital infections which can serve as
biological cofactors for the transmission of the human im-
munodeﬁciency virus (HIV) [15–17], and a cofactor in hu-
man papillomavirus (HPV) infection [18], screening pro-
grams for genital chlamydial infections may reduce the mor-
bidity associated with other sexual-transmitted pathogens in
women and help decrease the cost of reproductive as well as
general health care in developing countries, such as Iran.
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